On June 1, 2022 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, reported that it will present at the Jefferies Healthcare Conference being held June 8–10, 2022 (Press release, Cue Biopharma, JUN 1, 2022, View Source [SID1234615363]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Company will provide a corporate update highlighting the most recent clinical progress for CUE-101, its lead interleukin 2 (IL-2)-based CUE-100 series clinical drug candidate, being evaluated in a Phase 1b monotherapy trial and dose escalation trial in combination with KEYTRUDA for the treatment of patients with recurrent/metastatic HPV16+ head and neck cancer. The presentation will also focus on the Company’s second IL-2 based CUE-100 series clinical drug candidate, CUE-102, which recently received approval of an Investigational New Drug (IND) Application from the U.S. Food and Drug Administration (FDA). CUE-102 will be evaluated in a Phase 1 monotherapy dose escalation and expansion trial at a starting dose of 1mg/kg in patients with Wilms Tumor 1 (WT1)-positive recurrent/metastatic cancers.
Presentation Details
Jefferies Virtual Healthcare Conference
Date and Time: Friday, June 10 at 1:45–2:10 p.m. EDT in TRACK 2
Webcast Link: View Source
A live and archived webcast of the presentation will be available in the Investor and Media section of the Company’s website at www.cuebiopharma.com. The webcast will be archived for 30 days.
About the CUE-100 Series
The CUE-100 series consists of Fc-fusion biologics that incorporate peptide-MHC (pMHC) molecules along with rationally engineered IL-2 molecules. This singular biologic is anticipated to selectively target, activate and expand a robust repertoire of tumor-specific T cells directly in the patient. The binding affinity of IL-2 for its receptor has been deliberately attenuated to achieve preferential selective activation of tumor-specific effector T cells while reducing the potential for effects on regulatory T cells (Tregs) or broad systemic activation, potentially mitigating the dose-limiting toxicities associated with current IL-2-based therapies.